Literature DB >> 12435060

In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody.

S Welkos, A Friedlander1, S Weeks, S Little, I Mendelson1.   

Abstract

Antibodies (Abs) to the protective antigen (PA) component of the anthrax toxins have anti-spore as well as anti-toxin activities. Anti-PA antisera and purified anti-PA Abs enhance the phagocytosis by murine-derived macrophages (MQs) of spores of the Ames and Sterne strains and retard the germination of extracellular spores in vitro. The fate after phagocytosis of untreated and anti-PA-treated spores was further studied in culture medium that supported phagocytosis without stimulating spore germination (Dulbecco's minimal essential medium with horse serum 10%). The spores germinated within cells of primary peritoneal murine MQs (C3H/HeN) and MQs of the RAW264.7 MQ-like cell line; germination was associated with a rapid decline in spore viability. Exposure of MQs to inhibitors of phago-endosomal acidification (bafilomycin A and chloroquine) reduced the efficiency of MQ killing and allowed outgrowth and replication of the organisms. Treatment of spores with anti-PA Abs stimulated their phagocytosis and was associated with enhanced MQ killing of the spores. The enhanced killing of spores correlated with the greater extent of germination of anti-PA-treated spores after phagocytosis. A PA null mutant of the Ames strain exhibited none of the effects associated with anti-PA Ab treatment ofthe parental strain. Thus, the anti-PA Ab-specific immunity induced by vaccines has anti-spore activities and its role in impeding the early stages of infection with Bacillusanthracis needs to be assessed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435060     DOI: 10.1099/0022-1317-51-10-821

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  49 in total

1.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

2.  Morphogenesis of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Joel Bozue; Christopher Cote; Theresa Wenzel; Krishna-Sulayman Moody; Michael Mallozzi; Matthew Ryan; Rong Wang; Ryszard Zielke; Janine R Maddock; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.

Authors:  J Bozue; C K Cote; K L Moody; S L Welkos
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

4.  What is the relevance of lung epithelial cells during the dissemination of spores in inhalational anthrax?

Authors:  Jean-Nicolas Tournier; Aurélie Cleret; Anne Quesnel-Hellmann
Journal:  Infect Immun       Date:  2009-01       Impact factor: 3.441

5.  Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection.

Authors:  Christopher K Cote; Nico Van Rooijen; Susan L Welkos
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region.

Authors:  Robert Mabry; Mridula Rani; Robert Geiger; Gene B Hubbard; Ricardo Carrion; Kathleen Brasky; Jean L Patterson; George Georgiou; B L Iverson
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.

Authors:  Matthew A Crawford; Yinghua Zhu; Candace S Green; Marie D Burdick; Patrick Sanz; Farhang Alem; Alison D O'Brien; Borna Mehrad; Robert M Strieter; Molly A Hughes
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

8.  Deterministic models of inhalational anthrax in New Zealand white rabbits.

Authors:  Bradford Gutting
Journal:  Biosecur Bioterror       Date:  2014-02-14

9.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Four superoxide dismutases contribute to Bacillus anthracis virulence and provide spores with redundant protection from oxidative stress.

Authors:  Robert J Cybulski; Patrick Sanz; Farhang Alem; Scott Stibitz; Robert L Bull; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.